This Nano Cap Pharmaceutical Company Flags ‘Valuation Disconnect’ – But Retail Sees Upto 95% Upside From Record Lows

• The company said its NOOR Collagen supplement is projected to generate over $12 million in annualized revenue.
• Cosmos said the impact on operations due to the Middle East conflict is negligible.
• The firm is in the process of acquiring a Greece-based pharmacy distribution network.

Cosmos Health Inc (COSM) drew retail attention on Thursday after the company said it is exploring potential capital-raising options, including monetizing non-core assets, to address what it described as a “valuation disconnect”.

The company said its shares are currently trading well below book value, adding that its market capitalization does not fully reflect the strength of its operations or the value of its diversified asset base. Management said it may use proceeds to support strategic investments, acquisitions, and possible share buybacks.

COSM shares were up around 3% at $0.3. The company has a price-to-book ratio of 0.67 compared to the industry average of 4.48, according to Investing.com.

Cosmos’ Sky Premium Life Brand To Generate 75% Gross Margin

Cosmos Health expects gross margins of around 75% and strong cash flow from its U.S. operations for the Sky Premium Life brand. Sky Premium sells nutraceuticals, vitamins, and food supplements. The company said its NOOR Collagen supplement alone is projected to generate over $12 million in annualized revenue.

The company stated it is actively advancing its acquisition strategy, highlighted by a recent letter of intent to acquire a Greece-based pharmacy distribution network generating approximately $11.5 million in annual revenue. The move supports the company’s broader plan to scale operations and achieve its 2027 revenue target of $155.8 million.

Cosmos Health also said that the recent global geopolitical conflict has had a negligible impact on its operations.

How Did Stocktwits Users React?

Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, but chatter was mixed. One user expects a 90% to 95% increase in the stock’s price from its record lows of $0.28.

Another user said the stock has plenty of room to continue falling.

The stock has been under selling pressure so far this year, with shares down around 35%.

Read also: Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.